2012
DOI: 10.1517/13543784.2012.707189
|View full text |Cite
|
Sign up to set email alerts
|

Olaparib, PARP1 inhibitor in ovarian cancer

Abstract: Bad prognosis and drug resistance usually affect ovarian cancer. Recent trends toward the knowledge of molecular-specific pathways have produced new target drugs. PARP inhibition mediated by Olaparib in BRCA1 (breast cancer 1) and BRCA2 (breast cancer 2)-mutated and in sporadic ovarian cancer represents a promising field of investigation. Further studies are needed to confirm initial exciting results.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
27
0

Year Published

2013
2013
2016
2016

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 35 publications
(27 citation statements)
references
References 36 publications
0
27
0
Order By: Relevance
“…1). We then compared the efficacy of BMN 673 with that of olaparib, a PARP inhibitor that has previously been characterized in preclinical models of ovarian cancer [15], and determined that BMN 673 inhibits cell proliferation to a greater extent than olaparib (Supplemental Fig. 2), suggesting greater in vitro potency.…”
Section: Resultsmentioning
confidence: 99%
“…1). We then compared the efficacy of BMN 673 with that of olaparib, a PARP inhibitor that has previously been characterized in preclinical models of ovarian cancer [15], and determined that BMN 673 inhibits cell proliferation to a greater extent than olaparib (Supplemental Fig. 2), suggesting greater in vitro potency.…”
Section: Resultsmentioning
confidence: 99%
“…These combined therapeutic strategies frequently determine an impairment of patient mobility due to lymphoedema and nervous and vascular lower limb damage. In the era of personalized medicine, in which new cellular pathways have already been identified as key markers for new successful target therapies (38), increasing evidence is emerging regarding the identification of new biomarkers and their prognostic and predictive role in vulvar cancer (39). If confirmed on larger series, the direct association between CD133, the immunosuppressive pattern and tumour size and lymph node metastases could have several therapeutic implications that could include tailoring lymphadenectomy and introduce new immunological drugs.…”
Section: Discussionmentioning
confidence: 99%
“…December 2014 also saw European approval for AstraZeneca's olaparib (Lynparza), a first-in-class poly ADP ribose polymerase inhibitor, for use in the treatment of ovarian cancer [21,22]. This approval was notable in that European approval preceded US approval, albeit by just 7 days, as a consequence of the FDA's Oncology Drug Advisory Committee voting (in June 2014) to delay approval pending the results of a larger Phase III study.…”
Section: Oncology Indicationsmentioning
confidence: 99%
“…In addition to the drugs already discussed above the EMA's summary of 2014 also highlighted a further notable recommendation for approval [21]. Both of these are products for previously untreated conditions.…”
Section: Oncology Indicationsmentioning
confidence: 99%